Monocyte Regulation of Infant Immune Responses
Monocyte Regulation of Infant Immune Responses
批准号:
8891352
负责人:
MAKIO IWASHIMA
金额:
$42.29万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-20 至 2016-07-31
关键词:
AdjuvantAdultAgeAge-MonthsAgonistAntigensB-LymphocytesBindingBirthBloodCD14 geneCD3 AntigensCD36 geneCellsCessation of lifeChildChild SupportChildhoodCommunicable DiseasesDataDendritic CellsDevelopmentElderlyEmployee StrikesFrequenciesImmuneImmune responseImmune systemImmunityImmunocompromised HostImmunosuppressionImmunosuppressive AgentsInfantInfant MortalityInfectionInflammationLeadLifeLymphocyteMonitorMononuclearNatural ImmunityNeonatalPhenotypePlasmaPneumoniaPolysaccharidesPopulationReceptor SignalingRegulationRegulatory T-LymphocyteSignal TransductionStimulusT-LymphocyteTestingThrombospondin 1ToddlerTransforming Growth FactorsUmbilical Cord BloodVaccine AdjuvantVaccinesadaptive immunityagedbasecytokinehigh risk infantinfancymacrophagemicroorganismmonocytemortalityneonatepathogenperipheral bloodpreventreceptorresponsetool
中文摘要
描述(由申请人提供):传染病导致的婴儿死亡率导致全世界数百万6个月以下婴儿死亡。婴儿的免疫系统受到抑制,这使他们极易受到感染,并限制了他们对保护性和挽救生命的疫苗的免疫反应。外周血中的单核细胞分化为驱动适应性免疫的巨噬细胞和树突状细胞(DC),它们也可能为t非依赖性B细胞反应提供细胞因子支持。我们最近在脐带血中发现了两种单核细胞(CD14+), CD36hi和CD36lo,并表明CD36hi单核细胞驱动调节性T (Treg)细胞的发育。我们假设婴儿的免疫抑制状态部分是由于这些促进Treg细胞扩增的免疫抑制性CD36hi单核细胞占主导地位。我们还假设,在婴儿期,这些细胞对先天免疫信号反应不佳,无法支持t非依赖性(TI) B细胞反应。在Aim 1中,我们将检查由CD36hi单核细胞发起的先天免疫应答,以确定免疫抑制单核细胞损害婴儿先天免疫的程度。在Aim 2中,我们将监测婴儿期和整个儿童时期CD36hi单核细胞数量和功能的变化,并确定它们是否可以通过用病原体识别受体(PRR)激动剂刺激它们或通过阻断CD36与TSP1(一种诱导Treg细胞的潜伏TGF- -激活剂)的结合,从促进Treg细胞转化为效应T细胞;在Aim 3中,我们将确定CD36hi单核细胞是否不能支持TI B细胞反应,并确定用PPR激动剂治疗这些单核细胞是否可以诱导这些细胞支持TI B细胞反应。这些研究的结果有望为通过结合更有效的疫苗佐剂来克服婴儿的免疫抑制状态提供基础,这些佐剂将消除婴儿的免疫抑制状态并增强他们的免疫力。婴儿的一个主要缺陷是他们无法产生对多糖抗原的TI B细胞反应,如对链球菌肺炎的免疫所需要的反应,我们期望结果将确定诱导婴儿产生这种拯救生命的免疫反应的方法。
英文摘要
DESCRIPTION (provided by applicant): Infant mortality from infectious diseases results in millions of deaths worldwide in infants younger than six months of age. Infants have a suppressed immune system which makes them highly vulnerable to infections and limits their immune responses to protective and life-saving vaccines. Monocytes in peripheral blood differentiate to macrophages and dendritic cells (DC) which drive adaptive immunity, and they also likely provide cytokine support for T-independent B cell responses. We have recently identified two populations of monocytes (CD14+) in cord blood, CD36hi and CD36lo and shown that the CD36hi monocytes drive development of regulatory T (Treg) cells. We hypothesize that the immunosuppressive state of infants is due in part to the predominance of these immunosuppressive CD36hi monocytes which promote expansion of Treg cells. We also hypothesize that during infancy, these cells respond poorly to innate immune signals and are unable to support T-independent (TI) B cell responses. In Aim 1, we will examine the innate immune responses initiated by CD36hi monocytes to determine the extent to which innate immunity in infants is compromised by the immunosuppressive monocytes. In Aim 2, we will monitor changes in the number and function of CD36hi monocytes during infancy and throughout childhood, and determine if they can be converted from promoting Treg cells to effector T cells by stimulating them with pathogen recognition receptor (PRR) agonists or by blocking binding of CD36 to TSP1, an activator of latent TGF-� which induces Treg cells; and in Aim 3, we will determine if the CD36hi monocytes are unable to support TI B cell responses and determine if treatment of these monocytes with PPR agonists can induce these cells to support TI B cell responses. Results from these studies are expected to provide a basis for overcoming the immunosuppressive state of infants by a combination of more effective vaccine adjuvants that will abrogate the immunosuppressive state of infants as well as enhance their immunity. A major deficiency of infants is their inability to generate TI B cell responses to polysaccharide antigens such as is required for immunity to Streptococcal pneumonia, and we expect the results will identify the means to induce infants to generate such life-saving immune responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Function of Siglec 5 in T cell activation.
-
批准号:10373619
-
项目类别:
-
资助金额:$18.45万
-
财政年份:2022
-
负责人:MAKIO IWASHIMA
-
依托单位:
Function of Siglec 5 in T cell activation.
-
批准号:10665549
-
项目类别:
-
资助金额:$22.3万
-
财政年份:2022
-
负责人:MAKIO IWASHIMA
-
依托单位:
Immune checkpoint modulation by bacterial metabolites.
-
批准号:10246854
-
项目类别:
-
资助金额:$22.25万
-
财政年份:2020
-
负责人:MAKIO IWASHIMA
-
依托单位:
Immunomodulatory properties of umbilical cord blood
-
批准号:8606811
-
项目类别:
-
资助金额:$21.76万
-
财政年份:2013
-
负责人:MAKIO IWASHIMA
-
依托单位:
Immunomodulatory properties of umbilical cord blood
-
批准号:8461805
-
项目类别:
-
资助金额:$17.99万
-
财政年份:2013
-
负责人:MAKIO IWASHIMA
-
依托单位:
Monocyte Regulation of Infant Immune Responses
-
批准号:8299266
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2012
-
负责人:MAKIO IWASHIMA
-
依托单位:
Monocyte Regulation of Infant Immune Responses
-
批准号:8691718
-
项目类别:
-
资助金额:$42.98万
-
财政年份:2012
-
负责人:MAKIO IWASHIMA
-
依托单位:
Monocyte Regulation of Infant Immune Responses
-
批准号:8534025
-
项目类别:
-
资助金额:$42.82万
-
财政年份:2012
-
负责人:MAKIO IWASHIMA
-
依托单位:
Monocyte Regulation of Infant Immune Responses
-
批准号:9109561
-
项目类别:
-
资助金额:$51.54万
-
财政年份:2012
-
负责人:MAKIO IWASHIMA
-
依托单位:
Alcohol induced enrichment of regulatory T cells
-
批准号:7743353
-
项目类别:
-
资助金额:$7.48万
-
财政年份:2009
-
负责人:MAKIO IWASHIMA
-
依托单位:
Aging effect on PLD Signaling in T Cells
-
批准号:7334544
-
项目类别:
-
资助金额:$15.22万
-
财政年份:2007
-
负责人:MAKIO IWASHIMA
-
依托单位:
Aging effect on PLD Signaling in T Cells
-
批准号:7494108
-
项目类别:
-
资助金额:$14.92万
-
财政年份:2007
-
负责人:MAKIO IWASHIMA
-
依托单位:
Spatial control of Ca2+ signals in lymphocytes
-
批准号:6609439
-
项目类别:
-
资助金额:$10.73万
-
财政年份:2003
-
负责人:MAKIO IWASHIMA
-
依托单位:
Spatial control of Ca2+ signals in lymphocytes
-
批准号:7502928
-
项目类别:
-
资助金额:$10.84万
-
财政年份:2003
-
负责人:MAKIO IWASHIMA
-
依托单位:
Spatial control of Ca2+ signals in lymphocytes
-
批准号:7002670
-
项目类别:
-
资助金额:$31.42万
-
财政年份:2003
-
负责人:MAKIO IWASHIMA
-
依托单位:
Spatial control of Ca2+ signals in lymphocytes
-
批准号:6837711
-
项目类别:
-
资助金额:$32.18万
-
财政年份:2003
-
负责人:MAKIO IWASHIMA
-
依托单位:
Spatial control of Ca2+ signals in lymphocytes
-
批准号:6795571
-
项目类别:
-
资助金额:$32.18万
-
财政年份:2003
-
负责人:MAKIO IWASHIMA
-
依托单位:
Spatial control of Ca2+ signals in lymphocytes
-
批准号:7162500
-
项目类别:
-
资助金额:$20.07万
-
财政年份:2003
-
负责人:MAKIO IWASHIMA
-
依托单位:
Threshold control for T cell antigen receptor
-
批准号:6877773
-
项目类别:
-
资助金额:$10.85万
-
财政年份:2001
-
负责人:MAKIO IWASHIMA
-
依托单位:
Threshold control for T cell antigen receptor
-
批准号:6721417
-
项目类别:
-
资助金额:$10.85万
-
财政年份:2001
-
负责人:MAKIO IWASHIMA
-
依托单位:
海外基金